Quantumzyme (QTZM) Financials
Newest figures come from the 10-Q for Q3 FY2026, filed Jun 11, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the QTZM SEC filings page.
Quantumzyme Corp (QTZM) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest usable figures show a small revenue base where operating losses consumed cash despite limited balance-sheet leverage.
In FY2017, a net loss of$33K exceeded gross profit of$22K , showing that costs beyond direct production absorbed the entire gross profit. Operating cash flow was-$38K while financing cash flow was$41K , indicating that external funding supplied more cash than operations generated.
The 17.4% gross margin did not translate into profitability: net margin was
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
We do not publish a peer-relative financial health score for Quantumzyme Corp, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Quantumzyme Corp generated $0 in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Quantumzyme Corp earned $0.00 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Not reported for Q3 2026.
Cash & Balance Sheet
Quantumzyme Corp held $59 in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
None of these metrics is reported for Q3 2026.
Capital Allocation
None of these metrics is reported for Q3 2026.
QTZM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0n/m | $0n/m | $0n/m | N/A | $0n/m | $0 | $0 | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | $3K | $2K | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | -$25K | -$61K | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $5K | $5K | N/A |
| Income Tax | $0n/m | $0n/m | $0n/m | N/A | $0n/m | $0 | $0 | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | -$30Kn/m | -$66Kn/m | N/A |
| EPS (Basic) | N/A | N/A | N/A | N/A | $0.00n/m | N/A | N/A | N/A |
| EPS (Diluted) | $0.00n/m | -$0.12n/m | $0.00n/m | -$0.01 | $0.00 | $0.00 | $0.00 | N/A |
| Diluted Shares (Avg) | 35M0.0% | 35M0.0% | 39M+12.1% | N/A | 35M | 35M | 35M | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, EBITDA.
QTZM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K/A |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $59-89.9% | $59 | $184 | $584-94.2% | $584 | N/A | N/A | $10K |
| Current Assets | $59-89.9% | $59 | $184 | $584-94.2% | $584 | N/A | N/A | $10K |
| Cash & Equivalents | $59-89.9% | $59-96.6% | $184-96.4% | $584n/m | $584n/m | $2K | $5K | $0 |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 | $0 |
| Total Liabilities | $443K+10.0% | $418K | $491K | $441K+50.5% | $403K | N/A | N/A | $293K |
| Current Liabilities | $443K+10.0% | $418K | $491K | $441K+50.5% | $403K | N/A | N/A | $293K |
| Non-Current Liabilities | $0n/m | $0 | $0 | $0n/m | $0 | N/A | N/A | $0 |
| Total Equity | -$443Kn/m | -$418Kn/m | -$491Kn/m | -$441Kn/m | -$403K-108.4% | -$373K-107.7% | -$343K-107.1% | -$283K |
| Retained Earnings | -$10.0Mn/m | -$10.0M | -$5.7M | -$5.6Mn/m | -$5.6M | N/A | N/A | -$5.4M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
QTZM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
QTZM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Liabilities-to-Equity, FCF Margin.
Note: Shareholder equity is negative (-$441K), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Quantumzyme Corp QTZM | FY2025 | $0 | N/A | N/A | N/A | — |
| Sasol Ltd SASOF | FY2026 | $16.6B | $741.1M | 4.5% | $9.5B | — |
| BioLargo Inc BLGO | FY2025 | $7.8M | -$11.8M | N/A | $23.9M | — |
| Nocopi Techs Inc NNUP | FY2025 | $1.5M | -$155K | -10.4% | $17.9M | — |
Where Quantumzyme Corp Ranks
Frequently Asked Questions
Quantumzyme Corp (QTZM) reported $0 in total revenue for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Quantumzyme Corp (QTZM) had $584 in total assets as of fiscal year 2025, including both current and long-term assets.
Quantumzyme Corp (QTZM) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
Quantumzyme Corp (QTZM) has negative shareholder equity of -$441K as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.